Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer.

about

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer.

Item

http://www.wikidata.org/entity/Q42690881

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Objective measurement and clin ...... ceptor-positive breast cancer.

@en

Objective measurement and clin ...... ceptor-positive breast cancer.

@nl

type

Item

label

Objective measurement and clin ...... ceptor-positive breast cancer.

@en

Objective measurement and clin ...... ceptor-positive breast cancer.

@nl

prefLabel

Objective measurement and clin ...... ceptor-positive breast cancer.

@en

Objective measurement and clin ...... ceptor-positive breast cancer.

@nl

P1476

Objective measurement and clin ...... ceptor-positive breast cancer.

@en

P2093

Daniel E Carvajal-Hausdorf

http://www.w3.org/2001/XMLSchema#string

David L Rimm

http://www.w3.org/2001/XMLSchema#string

Nikita Mani

http://www.w3.org/2001/XMLSchema#string

Vamsidhar Velcheti

http://www.w3.org/2001/XMLSchema#string

P2860

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan

Prevention of allogeneic fetal rejection by tryptophan catabolism

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review.

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

P2888

s40425-017-0285-7

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40425-017-0285-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kurt A Schalper

P577

2017-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092036755

http://www.w3.org/2001/XMLSchema#string

P698

29037255

http://www.w3.org/2001/XMLSchema#string

P932

5644103

http://www.w3.org/2001/XMLSchema#string